

## **Press release**

**Zug, 11 December 2009**

### **HBM BioVentures portfolio company: Successful IPO for China Nuokang**

Trading in the shares of China Nuokang (NASDAQ: NKBP) started yesterday. China Nuokang's market valuation corresponds to almost double the current book value of HBM BioVentures' investment. HBM BioVentures sold half of its shares in the IPO. The proceeds repaid almost all of the original USD 3.75 million investment.

HBM BioVentures invested a total of USD 3.75 million at USD 5.27 per share in China Nuokang Bio-Pharmaceutical Inc. in December 2007. Going public on the US NASDAQ exchange involved the placement of a total of USD 45 million in new and existing shares in the form of American Depositary Shares. The sale of half of its holding in China Nuokang at the IPO price of USD 9.-- yields an immediate USD 3.2 million in cash for HBM BioVentures. In addition, HBM remains invested in China Nuokang with an ongoing holding of 355,000 shares which correspond to approximately 1.7% of the company overall.

China Nuokang develops, manufactures and markets products that focus on the cardiovascular markets in China. Its lead drug, Baquting, is the number one hemocoagulase product in China used for bleeding control. Baquting is produced on the basis of snake venom. China Nuokang will use the proceeds from the IPO to expand its sales and marketing platform, M&A activities, R&D and general corporate purposes. For more information on China Nuokang, please consult [www.nkbp.com](http://www.nkbp.com).

For further information, please contact Dr. Andreas Wicki, CEO HBM BioVentures Ltd, tel.: +41 41 768 11 08, [andreas.wicki@hbmbioventures.com](mailto:andreas.wicki@hbmbioventures.com).

#### **HBM BioVentures Ltd**

As a venture capital company, HBM BioVentures is invested globally in some 35 mature emerging companies in the biotechnology/human medicine, diagnostics and medical technology sectors. The lead products of HBM BioVentures' portfolio companies are either at an advanced stage of development or already available on the market. The company focuses on emerging companies that are not yet listed, with two-thirds of assets invested in private companies that offer high value creation potential. This has enabled HBM BioVentures to carve out a unique and distinctive market position. HBM BioVentures has a broad shareholder base and is listed on the SIX Swiss Exchange (ticker: HBMN). Visit [www.hbmbioventures.com](http://www.hbmbioventures.com).

**NOT FOR DISTRIBUTION IN THE USA, CANADA, JAPAN OR AUSTRALIA**



**Disclaimer**

This media release does not constitute an issue prospectus within the meaning of Art. 652a or Art. 1156 of the Swiss Code of Obligations, a listing prospectus in the sense of the SIX Swiss Exchange Listing Rules or a securities prospectus as defined in the German Securities Prospectus Act (*Wertpapierprospektgesetz*). Publication is for information purposes only and constitutes neither an offer to sell nor an invitation to buy or subscribe for securities. This media release and the information it contains must not be distributed or forwarded to or within the United States of America (USA) or to US persons (including legal entities) or publications with a general circulation in the USA. This media release does not constitute an offer or invitation to purchase any securities in the USA. The securities of HBM BioVentures Ltd have not been registered under United States securities legislation and may not be offered, sold or delivered within the USA or to US persons without prior registration or the corresponding exemption from the registration requirements of US securities legislation.

HBM BioVentures Ltd  
Bundesplatz 1  
CH-6300 Zug / Switzerland  
Tel:+41 41 768 11 08  
Fax:+41 41 768 11 09  
[info@hbmbioventures.com](mailto:info@hbmbioventures.com)  
[www.hbmbioventures.com](http://www.hbmbioventures.com)